



## **Optibrium strengthens senior management team with Financial Director appointment**

**CAMBRIDGE, UK, 28 January 2019** – Optibrium™, a developer of software for drug discovery, today announced the appointment of Clare Devlin as Financial Director. The new role supports the company's sustained rapid growth and ambitious expansion plans, driven by the success of its StarDrop™ software.

As well as managing all financial aspects of the business, Clare will be part of the senior team developing business strategy and objectives. Clare brings a wealth of commercial experience, having held Financial Director roles at Scintacor, Adviso and Genestack, where she developed and implemented effective business strategies. She specialises in business advice, management and financial accounting, business planning, forecasting and restructuring.

Last year saw Optibrium relocate its Headquarters and R&D facilities to larger premises in Cambridge, UK, with the capacity to accommodate future growth. Newly extended offices have allowed Optibrium to invest further in accelerating its R&D pipeline by expanding the team with three additional software engineers.

The company launched the latest version of its lead product, StarDrop™ 6.5, last year and is developing new product features for introduction later this year. The extra office space is set to accommodate these developments, as well as new strategic partnerships and collaborations.

**Dr. Matthew Segall, CEO at Optibrium, said:** "The appointment of Clare and the strengthening of our software development team form part of ambitious growth plans and mission to accelerate our R&D pipeline. This will enable us to extend our research into new technologies that improve the efficiency and productivity of the drug discovery process.

"As the company matures, we're investing in key senior and technical roles to maintain corporate development and help bring new product features to our clients quicker. I am delighted to welcome the new members of our multidisciplinary team."

**Clare Devlin, Optibrium's newly appointed Financial Director, added:** "Optibrium's rapid revenue growth in 2018 has set a great foundation for further growth this year. I look forward to assisting the Company with their continued business development and corporate expansion."

For further information about Optibrium, please visit [www.optibrium.com](http://www.optibrium.com) , or contact [info@optibrium.com](mailto:info@optibrium.com)

**ENDS**

**Notes to Editors:**



*Clare Devlin*  
*Financial Director*  
*Optibrium*

For high resolution images please email [sarah.jeffery@zymecommunications.com](mailto:sarah.jeffery@zymecommunications.com)

To opt-out from receiving press releases from Zyme Communications please email [info@zymecommunications.com](mailto:info@zymecommunications.com) . To view our privacy policy please [click here](#).

**Media contact**

Sarah Jeffery  
Zyme Communications  
E-mail: [sarah.jeffery@zymecommunications.com](mailto:sarah.jeffery@zymecommunications.com)  
Phone: +44 (0) 7771 730919

**Optibrium**

Nick Foster  
Head of Commercial Operations  
E-mail: [nick.foster@optibrium.com](mailto:nick.foster@optibrium.com)  
Phone: +44 (0)1223 815900

**About Optibrium Ltd**

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. The company's lead product, StarDrop, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process.

Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston and San Francisco, USA. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.

For further information visit [www.optibrium.com](http://www.optibrium.com) or join in discussions on improving the productivity of drug discovery at [www.optibrium.com/community](http://www.optibrium.com/community)